Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 370 results for "erbitux"

Merck KGaA Names Pharmaceutical Head Oschmann Deputy CEO

Merck KGaA, the German maker of Erbitux cancer medicine, promoted Stefan Oschmann to deputy chief executive officer and appointed Belen Garijo as its first female board member. Oschmann, currently head of the pharmaceutical unit, and Garijo, now ... BusinessWeek, 4 days ago

3 images for "erbitux"

Cancernetwork.com, 2 weeks ago
Drug Discovery and Development, 1 month ago
Pharma Letter, 2 months ago

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Revision: 23, Authorised

Erbitux : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2009-07-14 2014-08-14 ...
 European Medicines Agency1 month ago

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had ...
 CancerConnect.com1 month ago New treatment combination benefited patients with lung cancer resistant to EGFR inhibitors  Ecancer Medicalscience1 month ago New Treatment Combination Benefits Patients With EGFR Inhibitors  Advance for Respiratory Care & Sleep Medicine1 month ago Afatinib plus cetuximab shows promise for EGFR -mutated lung cancer  Orthopedics Today1 month ago

German Firms Go on U.S. Buying Spree

By Daniel Michaels And Shayndi Raice FRANKFURT--German companies are on a buying spree--and the U.S. is their biggest target. On Monday, pharmaceutical firm Merck KGaA said it would buy Sigma Aldrich Corp., a life-sciences company based in St.
 4 Traders2 hours ago
[x]  

Does An Acquisition Of Sigma-Aldrich Make Merck Worth Considering?

Summary Merck announced Monday that it would acquire Sigma-Aldrich for $17 billion. The deal marks the largest takeover in Merck's history, and it could be its most successful. Acquiring Sigma-Aldrich allows Merck to develop its chemicals ...
 Seeking Alpha7 hours ago Merck KGaA pays out $17 billion for Sigma-Aldrich  Pharmafocus9 hours ago Merck KGaA to Acquire Sigma-Aldrich for $17B in Cash  Mergers & Acquisitions11 hours ago Merck KGaA to Buy Sigma-Aldrich for $17 Billion to Add Chemicals  BusinessWeek12 hours ago
[x]  
Seeking Alpha

Merck on Track with Pharma Strategy

Pipeline Progress Announced 22-09-2014: Merck announced that its biopharmaceutical division Merck Serono is well on track with the implementation of the Group's Fit for 2018 transformation and growth program. This is reflected by efficiency gains ...
 Bionity.com20 hours ago Merck KGaA : on Track with Pharma Strategy; Pipeline Progress Announced  4 Traders4 days ago Merck KGaA Says On Track With Pharma Strategy  Pharmacy Choice4 days ago MERCK KGAA : acute;s Biopharmaceutical Division Announces Groundbreaking of New Pharmaceutical Manufacturing Facility in China, its Second Largest Worldwide  4 Traders3 weeks ago

Is Merck KGaA on Track with its "Fit for 2018" Program?

Merck KGaA ( MKGAF ) provided an update on its Fit for 2018 transformation and growth program. The company said that its biopharmaceutical division, Merck Serono, remains on track for the program. The company discussed its plans regarding the ...
 Yahoo! Finance3 days ago

Dimension Therapeutics Appoints New CEO,

Dr. Annalisa Jenkins CAMBRIDGE, MASS., September 16, 2014 Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced that Annalisa Jenkins, MBBS, MRCP has been appointed as chief ...
 BioSpace6 days ago Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer  Crawford Financial Planning6 days ago Dimension Therapeutics : Names Annalisa Jenkins as Chief Executive Officer  4 Traders6 days ago
[x]  

Is that trader flashing a sell sign?

By | CNBC The easiest million dollars I ever made in the market was beneath the rubble of Martha Stewart and Sam Waksal. It was late December 2001, and the people in the know had already sold their shares of ImClone due to the FDA's rejection ...
 Yahoo! Malaysia6 days ago

Cetuximab plus radiation, cisplatin yielded little benefit in advanced head and neck cancers

The addition of cetuximab to cisplatin-based radiation therapy conferred no significant benefit with regard to PFS, OS, locoregional failure or distant metastasis in patients with stage III or stage IV head and neck carcinoma, according to results ...
 Orthopedics Today1 week ago Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234  Journal of Clinical Oncology2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less